List of Excipients in Branded Drug CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE

Generic Drugs Containing CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0003	ALCOHOL
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0003	FD&C BLUE NO. 1
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0003	GLYCERIN
Xttrium Laboratories Inc	chlorhexidine gluconate	0116-0003	PEG-40 SORBITAN DIISOSTEARATE

What are the Most Frequently-Used Excipients in CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE?

# Of NDCs	Excipient
4	ALCOHOL
4	FD&C BLUE NO. 1
4	GLYCERIN
4	PEG-40 SORBITAN DIISOSTEARATE

Chlorhexidine Gluconate 0.12% Oral Rinse: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 5, 2026

Chlorhexidine gluconate 0.12% oral rinse is a mature prescription oral-care product with limited active-ingredient protection and low formulation complexity. Commercial differentiation depends on excipient selection, tolerability, alcohol reduction, flavor performance, packaging, institutional channels and evidence for use in specific dental settings. The strongest opportunities are alcohol-free formulations, improved taste and stain management, unit-dose delivery, preservative optimization and private-label supply.

What is chlorhexidine gluconate 0.12% oral rinse?

Chlorhexidine gluconate 0.12% oral rinse is an aqueous oral antiseptic used as part of a professional program for reducing gingival inflammation and managing plaque-associated periodontal disease. The reference U.S. product is Peridex, marketed by 3M Health Care under NDA 19-794. The product is prescription-only and is not approved as a general over-the-counter mouthwash.[1]

The active concentration is 0.12% chlorhexidine gluconate, equivalent to 1.2 mg/mL of chlorhexidine gluconate solution. The labeled dose is generally 15 mL used for 30 seconds twice daily after toothbrushing, followed by expectoration.[1]

What are the main clinical and commercial limitations?

The principal limitations are:

• Tooth and oral-surface staining
• Altered taste perception
• Increased calculus formation in some users
• Alcohol content in several legacy formulations
• Short-term rather than chronic-use positioning
• Need for professional instruction and prescription distribution

These limitations create the primary formulation and commercial opportunities. A new product does not need a new active ingredient to compete. It needs a clinically acceptable improvement in use experience, administration or distribution.

What excipients are used in 0.12% chlorhexidine oral rinse?

The Peridex label identifies chlorhexidine gluconate, water, alcohol, glycerin, PEG 600, polysorbate 20, flavor, sodium saccharin and FD&C Green No. 3 as inactive ingredients.[1] The excipient system performs several functions:

Excipient or excipient class	Primary function	Commercial relevance
Purified water	Vehicle	Controls clarity, microbial quality and mouthfeel
Ethanol	Solvent and antimicrobial preservation aid	Creates alcohol-free differentiation opportunity
Glycerin	Humectant and mouthfeel modifier	Can reduce harshness and improve viscosity
PEG 600	Solubilizer and texture modifier	Supports flavor and active distribution
Polysorbate 20	Surfactant and flavor solubilizer	Helps maintain formulation uniformity
Flavor system	Taste masking	Key determinant of adherence
Sodium saccharin	High-intensity sweetener	Reduces bitterness without adding fermentable sugar
FD&C Green No. 3	Colorant	Supports product identification but adds regulatory and consumer-preference considerations

A formulation must preserve chlorhexidine activity while avoiding precipitation, adsorption to packaging, excessive foaming and unacceptable sensory effects. Chlorhexidine is cationic, so anionic excipients and anionic flavor or detergent systems require particular scrutiny. Incompatible ingredients may reduce free chlorhexidine or produce visible precipitation.

How should manufacturers design an excipient strategy?

The preferred development strategy is to preserve the 0.12% active concentration while improving tolerability and manufacturability.

Alcohol-free vehicle

An alcohol-free formulation is the most direct opportunity. Ethanol removal can improve acceptance among patients who experience burning, dry mouth or alcohol sensitivity. It also expands positioning in dental practices that prefer alcohol-free products.

Removing ethanol creates technical requirements:

• Reoptimization of chlorhexidine solubility
• Alternative preservation strategy
• Microbial challenge testing
• Stability testing in multidose packaging
• Assessment of active adsorption and container interaction
• Rebalancing of flavor intensity and mouthfeel

An alcohol-free product cannot be treated as a simple ethanol deletion. The vehicle, preservative system and flavor package may all require reformulation.

Taste and mouthfeel

Taste masking is commercially important because chlorhexidine can produce bitterness and temporary taste disturbance. A more effective system may combine:

• Low-irritancy flavor oils or water-soluble flavors
• Controlled sweetener levels
• Glycerin or other humectants
• Reduced solvent harshness
• Lower foam generation
• Flavor systems that minimize lingering aftertaste

Flavor selection must be assessed against chlorhexidine compatibility, oral mucosal irritation, stability and packaging sorption. Strong flavor intensity may improve initial perception but can create burning or persistent aftertaste.

Stain-management positioning

Chlorhexidine-associated staining is a product-class problem. A manufacturer may investigate excipients that reduce surface deposition or support easier removal, but any such approach requires evidence that chlorhexidine antimicrobial activity is maintained.

Potential development directions include:

• Lower-residue flavor and surfactant systems
• Reduced pigment load
• Improved rinsability
• Adjunctive polishing or professional-cleaning protocols
• Packaging and instructions that reduce misuse or prolonged exposure

Claims that imply reduced staining, improved tolerability or superior plaque control would require appropriate comparative data and FDA review.

Preservative strategy

Alcohol-free products require a defensible microbiological-control strategy. Options may include a compatible preservative, antimicrobial packaging, single-use containers or a formulation with validated microbiological robustness.

The choice must account for:

• Compatibility with cationic chlorhexidine
• Oral safety
• Preservative efficacy
• pH stability
• Container closure performance
• Regulatory acceptability
• Consumer sensitivity and clean-label expectations

A single-use unit-dose package can reduce the preservative burden, but it increases packaging cost, shipping volume and environmental considerations.

What formulations are protected by patents?

The active ingredient and 0.12% concentration are mature technologies. Chlorhexidine has been used in oral-care and healthcare products for decades, and the basic composition is unlikely to provide meaningful blocking patent protection in the United States.

Current patent position

The commercial patent risk is generally lower than the regulatory and execution risk. A competitor developing a standard 0.12% rinse would normally examine:

Protection category	Likely competitive significance
Chlorhexidine gluconate active ingredient	Low; mature and broadly known
0.12% aqueous rinse	Low unless combined with a novel formulation limitation
Alcohol-free formulation	Potentially moderate if supported by a genuinely novel composition
Stain-reduction system	Potentially moderate, depending on claims and evidence
Unit-dose packaging	Potentially protectable, but usually narrow
Specific preservative system	Potentially protectable if technically distinctive
Flavor and sensory system	Usually difficult to defend broadly
Manufacturing process	Relevant if it solves stability or uniformity problems
Method of use	Narrower opportunity because many oral-rinse uses are established

Any freedom-to-operate assessment must review active U.S. patents, published applications, Orange Book-listed patents for the relevant reference product and third-party patents covering preservatives, packaging and formulation components. The absence of strong active-ingredient patents does not eliminate risk from formulation or device claims.

What is the FDA regulatory status of chlorhexidine gluconate 0.12% rinse?

Peridex is an FDA-approved prescription oral rinse. Generic products may enter through the abbreviated new drug application pathway if they demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA’s applicable requirements for the product.[1][2]

Key regulatory considerations include:

• Same active ingredient and strength
• Same dosage form and route
• Comparable inactive-ingredient safety
• Equivalent labeling unless FDA permits an allowable difference
• Stability through the proposed shelf life
• Microbial quality and preservative effectiveness
• Container-closure suitability
• Manufacturing under current good manufacturing practice

For an ANDA, excipient differences may be possible, but they cannot create a safety concern or materially alter product performance. Novel claims, new delivery systems or substantial clinical differentiation may move the product toward a 505(b)(2) strategy rather than a conventional ANDA.

What is the Orange Book status and exclusivity position?

The reference product is an old prescription product with no meaningful remaining new chemical entity exclusivity. The central commercial question is patent listing, not statutory exclusivity.

Exclusivity or protection	Commercial assessment
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	No meaningful current barrier expected
Reference-product data exclusivity	Expired
Orange Book patent barrier	Must be verified against the current FDA listing
Generic approval pathway	ANDA, subject to FDA requirements
505(b)(2) opportunity	Possible for materially differentiated delivery or formulation

A Paragraph IV challenge would be relevant only if an ANDA applicant certifies that a listed patent is invalid, unenforceable or not infringed. For a mature product with limited listed-patent protection, the principal entry risks may instead involve FDA review deficiencies, manufacturing readiness, product quality and commercial contracting.

When does chlorhexidine gluconate 0.12% lose exclusivity?

The product’s core exclusivity has already expired. Generic competition is therefore legally feasible, subject to FDA approval and any remaining listed patents. The commercial launch date depends on ANDA approval, applicant certification, potential litigation, manufacturing capacity and customer contracts.

Because the product is mature, entry does not require a competitor to wait for a future loss-of-exclusivity date. A company can pursue market entry now if it can meet regulatory and commercial requirements.

Which companies are competing in the market?

Competition includes the reference brand, authorized or branded-generic suppliers, dental wholesalers, contract manufacturers and private-label providers. The market is fragmented by channel rather than dominated solely by molecular innovation.

Relevant channels include:

• Dental practices
• Periodontists and oral surgeons
• Hospitals
• Long-term-care facilities
• Specialty pharmacies
• Dental-service organizations
• Government and institutional procurement
• Private-label dental distributors

The most defensible commercial position may come from supply reliability, contract pricing, unit-dose packaging and clinician acceptance rather than brand advertising.

What commercial opportunities exist for excipient-led products?

Alcohol-free prescription rinse

This is the clearest opportunity. The product can target patients with alcohol sensitivity, xerostomia concerns, burning complaints or preference for alcohol-free oral care. The label must remain consistent with the approved indication and supported evidence.

Premium taste and tolerability

A differentiated sensory profile can improve refill behavior and dental-office recommendations. Commercial claims should focus on measurable attributes such as alcohol-free composition, flavor preference or reduced sensory irritation if supported by studies.

Unit-dose institutional product

Single-use cups or sachets can reduce dosing errors and improve infection-control handling. The product may fit hospitals, surgical centers, nursing facilities and dental practices with high patient throughput.

Private-label and contract manufacturing

A manufacturer with validated chlorhexidine capability can supply dental distributors under private labels. This model can reduce commercial acquisition costs and use existing manufacturing infrastructure.

Pediatric and special-population positioning

A lower-irritancy, alcohol-free formulation may attract interest from caregivers and clinicians, but pediatric or special-population claims require careful regulatory and clinical support. Chlorhexidine use remains subject to professional direction and product labeling.

How strong is the patent estate for chlorhexidine 0.12% oral rinse?

The patent estate is generally weak around the basic product and potentially stronger around narrowly claimed improvements. The most defensible assets would likely cover:

1. A specific alcohol-free composition with demonstrated stability.
2. A preservative system compatible with chlorhexidine.
3. A validated stain-reduction formulation.
4. A unit-dose or dispensing system.
5. A manufacturing process that improves uniformity or shelf life.
6. A formulation with comparative clinical or sensory evidence.

Patent value depends on claim breadth, freedom from prior art and the ability to detect infringement. Broad claims to chlorhexidine, water, sweetener and flavor are vulnerable because the technology is longstanding.

What generic launch risks exist?

The main risks are operational:

• Failure to match the reference product’s stability
• Incompatibility between chlorhexidine and excipients
• Microbial contamination in alcohol-free multidose products
• Flavor dissatisfaction
• Packaging adsorption or leakage
• FDA questions about inactive ingredients
• Inadequate commercial supply
• Difficulty obtaining dental-practice conversion
• Limited reimbursement or formulary differentiation
• Professional concern about staining and taste

A generic can obtain approval yet fail commercially if it lacks reliable supply or does not secure dental-distributor placement.

How does chlorhexidine rinse compare with competing oral antiseptics?

Product category	Active technology	Prescription status	Main advantage	Main limitation
Chlorhexidine 0.12% rinse	Chlorhexidine gluconate	Generally prescription	Established periodontal-use evidence	Staining and taste effects
Essential-oil rinse	Essential oils	Often OTC	Broad consumer availability	Different clinical positioning
Cetylpyridinium chloride rinse	Quaternary ammonium compound	Often OTC	Consumer familiarity	Less direct substitution in professional protocols
Povidone-iodine rinse	Iodophor	Varies by market and use	Broad antiseptic activity	Taste, staining and population restrictions
Hydrogen peroxide rinse	Oxidizing agent	Often OTC	Low-cost and familiar	Limited suitability for sustained periodontal management

Chlorhexidine retains a professional-use advantage because clinicians recognize its established role. Competing products may have better consumer tolerability and broader retail access.

Key Takeaways

• Chlorhexidine gluconate 0.12% oral rinse is a mature prescription product with expired core exclusivity.
• The reference excipient system includes water, alcohol, glycerin, PEG 600, polysorbate 20, flavor, sodium saccharin and colorant.
• The strongest formulation opportunity is an alcohol-free, lower-irritancy product with improved flavor and validated microbiological stability.
• Patent protection is likely to be narrow around specific excipient combinations, stain-reduction systems, packaging or manufacturing processes.
• Generic entry is legally feasible, but commercial success depends on supply reliability, dental-channel access and sensory performance.
• Biosimilar risk is irrelevant because chlorhexidine gluconate is a small-molecule active, not a biologic.
• A standard product is more suited to an ANDA strategy; a materially differentiated delivery or formulation system may support a 505(b)(2) approach.

FAQs

Is chlorhexidine gluconate 0.12% oral rinse an OTC product?

In the United States, the principal approved 0.12% prescription products are prescription oral rinses. OTC antiseptic mouthwashes with other actives are not direct regulatory substitutes.

Can ethanol be removed from chlorhexidine oral rinse?

Yes, but ethanol removal requires reformulation of solubility, preservation, stability, flavor and packaging. It should not be treated as a simple excipient deletion.

Which excipient creates the greatest formulation risk?

Anionic ingredients create a major compatibility risk because chlorhexidine is cationic. Surfactants, flavors, preservatives and other excipients must be screened for precipitation, binding and loss of antimicrobial activity.

Can a company patent a new chlorhexidine mouthwash?

Potentially, if the formulation contains a novel and non-obvious composition or process that provides a measurable technical benefit. Broad claims to chlorhexidine, water and conventional sweeteners are unlikely to provide strong protection.

Is a 0.12% chlorhexidine rinse suitable for long-term consumer use?

The product is generally used under dental-professional direction. Long-term routine consumer use is limited by staining, taste disturbance and other tolerability concerns described in product labeling.[1]

References

1. 3M Health Care. (2022). Peridex chlorhexidine gluconate oral rinse, 0.12%: Prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. U.S. Department of Health and Human Services.

4. Jones, C. G. (1997). Chlorhexidine: Is it still the gold standard? Periodontology 2000, 15(1), 55-62.

5. James, P., Worthington, H. V., Parnell, C., Harding, M., Lamont, T., Cheung, A., & Beirne, P. V. (2017). Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database of Systematic Reviews, 3, CD008676.